Aptose Biosciences Stock Price, News & Analysis (NASDAQ:APTO)

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" APTO shares.
View APTO analyst ratings or view top-rated stocks.

6 Wall Street research analysts have issued 12 month target prices for Aptose Biosciences' shares. Their APTO share price targets range from $12.00 to $120.00. On average, they predict the company's stock price to reach $37.67 in the next twelve months. This suggests a possible upside of 1,394.7% from the stock's current price.
View analysts price targets for APTO or view top-rated stocks among Wall Street analysts.

Aptose Biosciences' stock was trading at $8.70 at the beginning of 2023. Since then, APTO stock has decreased by 71.0% and is now trading at $2.52.
View the best growth stocks for 2023 here.

Aptose Biosciences saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 30,500 shares, a drop of 27.2% from the October 31st total of 41,900 shares. Based on an average trading volume of 37,400 shares, the days-to-cover ratio is currently 0.8 days. Currently, 1.0% of the company's shares are sold short.
View Aptose Biosciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our APTO earnings forecast.

Aptose Biosciences Inc. (NASDAQ:APTO) posted its quarterly earnings results on Thursday, March, 23rd. The biotechnology company reported ($1.65) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.65). During the same quarter in the previous year, the business earned ($4.05) EPS.

Aptose Biosciences's stock reverse split before market open on Tuesday, June 6th 2023. The 1-15 reverse split was announced on Tuesday, June 6th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

8 employees have rated Aptose Biosciences Chief Executive Officer William G. Rice, Ph.D. on Glassdoor.com. William G. Rice, Ph.D. has an approval rating of 34% among the company's employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 52.0% of employees surveyed would recommend working at Aptose Biosciences to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), Cisco Systems (CSCO), Micron Technology (MU) and SCYNEXIS (SCYX).

Aptose Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Sigma Planning Corp (1.93%), Annandale Capital LLC (0.99%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bernd R Seizinger, Denis R Burger, Donald R Jr Wilson, Erich Platzer, Rafael Bejar, Warren Whitehead and William G Rice.
View institutional ownership trends.

Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.